Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06368648 · ClinicalTrials.gov registry record
CoMind Early Feasibility Study
A clinical trial of Stroke and Traumatic Brain Injury, sponsored by CoMind Technologies Limited.
- Recruiting
- Registry status
- 581
- Enrollment target
- 14
- Study locations
NCT06368648: Recruiting study of Stroke and Traumatic Brain Injury, sponsored by CoMind Technologies Limited.
NCT06368648 is a study of Stroke and Traumatic Brain Injury that is actively recruiting participants, run by CoMind Technologies Limited. The registered enrollment target is 581 participants, below the 12,015-participant average among 454 other Stroke trials with a reported enrollment target (95% lower). The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06368648, a study of Stroke and Traumatic Brain Injury, is actively recruiting participants, sponsored by CoMind Technologies Limited.
- RECRUITING
- Registry status
- 581 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this research, which has been determined as non-significant risk by the central IRB overseeing the study, is to obtain information to help further develop a machine (a medical device) to measure the pressure around the brain from the outside (this pressure is called intracranial pressure or ICP). Monitoring and managing ICP is an important part of care for patients with conditions such as Traumatic Brain Injury (TBI). However, the current way of measuring ICP requires surgery to drill a hole into the skull, and therefore can introduce additional risks such as infections and pain. Recent research has shown it may be possible to measure ICP without needing surgery. This technology is in development, but large amounts of data is required to build these new devices. Through collecting a large database of information from patients who have both the routine surgical device and the research device applied to their head, the research team will work to develop and test an effective and potentially safer way of monitoring patient ICP.
Conditions Studied
Study Locations (14)
New York
- Albany Medical College - Albany
- Stony Brook University Hospital - Stony Brook
California
- UC Davis Medical Center - Sacramento
Delaware
- Christiana Care - Wilmington
District of Columbia
- Medstar Health - Washington D.C.
Florida
- Jackson Memorial Hospital - Miami
Kansas
- The University of Kansas Medical Center - Kansas City
Missouri
- Washington University Medical Center - St Louis
North Carolina
- WakeMed - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2026-11 |
What NCT06368648 shows while recruiting
NCT06368648 is an observational study that tracks outcomes without assigning an intervention. The registered 581 participants enrollment target is mid-sized for trials with a published cap, below the 12,015-participant average among 454 other Stroke trials with a reported enrollment target (95% lower).
The record links to 9 conditions, with Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT06368648 lists 14 locations in 13 states (New York, California, Delaware).
Frequently Asked Questions
What is clinical trial NCT06368648 about?
NCT06368648 is a clinical study titled "CoMind Early Feasibility Study". The purpose of this research, which has been determined as non-significant risk by the central IRB overseeing the study, is to obtain information to help further develop a machine (a medical device) to measure the pressure around the brain from the outside (this pressure is called intracranial press...
What is the current status of trial NCT06368648?
This trial is currently recruiting. The enrollment target is 581 participants. The study started on 2024-11-27. Estimated completion is 2026-11.
What conditions does trial NCT06368648 study?
This clinical trial studies the following conditions: Stroke, Traumatic Brain Injury, Intracerebral Hemorrhage, Hydrocephalus, Encephalopathy.
Who is sponsoring clinical trial NCT06368648?
This trial is sponsored by CoMind Technologies Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06368648 being conducted?
This trial has 14 study locations across California, Delaware, District of Columbia, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06368648's enrollment target sits among peer trials
581 52nd of 454 higher than 403 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI